Lantheus Holdings, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsLantheus Holdings, Inc. is a radiopharmaceutical-focused company commercializing imaging agents and microbubble diagnostics, now set to be acquired by Curium in an all-cash transaction.
What they do
Lantheus develops and sells diagnostic radiopharmaceuticals and microbubble contrast agents, operating across three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products are used primarily in cardiology, oncology, and neurology imaging. The company sells in the U.S. through direct distribution and internationally via direct sales and third-party distributors.
Revenue drivers
- PYLARIFY (piflufolastat F-18) — PSMA-targeted PET imaging agent for prostate cancer; Q2 2026 sales were $240.4M, down 4.1% YoY, and represents the largest product line.
- DEFINITY — Ultrasound contrast agent; Q2 2026 sales were $88.3M, up 5.2% YoY.
- Neuraceq — PET imaging agent for beta-amyloid plaque in the brain; Q2 2026 sales were $39.6M.
Recent performance
For Q2 2026, worldwide revenue rose 2.7% to $388.2M from $378.0M a year earlier. GAAP net income was $75.0M, down from $78.8M, with GAAP diluted EPS of $1.11 versus $1.12. Adjusted diluted EPS declined 1.3% to $1.55. Operating income increased 13.9% to $100.2M, while adjusted operating income fell 6.9% to $142.0M.
Strategy
Lantheus is focusing on radiopharmaceutical oncology and microbubbles after completing the sale of its SPECT business (TechneLite, NEUROLITE, Xenon Xe-133 Gas, Cardiolite) to SHINE Technologies on January 1, 2026. The company is advancing a pipeline including LNTH-2501 (PDUFA March 29, 2026) and MK-6240 (tau PET agent for Alzheimer's, PDUFA August 13, 2026). It also licensed PYLARIFY rights to GE Healthcare in Japan for development and commercialization. On August 3, 2026, Lantheus agreed to be acquired by Curium US Holdings for $102.50 per share plus CVRs of up to $12.00 per share, subject to milestones.
Risks
- Deal execution risk — The proposed Curium merger is subject to shareholder approval and regulatory clearances; failure to close could disrupt operations and share price.
- PYLARIFY competitive pressure — Sales of PYLARIFY declined 4.1% in Q2 2026, and increased competition from other PSMA agents could pressure future revenue.
- Regulatory approval delays — Pipeline products like LNTH-2501 and MK-6240 have PDUFA dates in 2026; any delay or non-approval could hurt growth prospects.
- SPECT divestiture transition — The sale of the SPECT business reduces revenue diversification and introduces integration and supply chain transition risks.
Outlook
Management suspended full-year 2026 financial guidance in connection with the pending Curium acquisition. The company expects the transaction to close pending approvals, creating a combined radiopharmaceutical company serving patients in over 70 countries. No conference call was held for Q2 2026 results due to the pending deal.